PegBio Co., Ltd. reported that its internally developed candidate CR059 has been accepted as a Late Breaking Abstract for poster presentation at the 2026 Scientific Sessions of the American Diabetes Association (ADA).

The abstract, titled “CR059, a Once-Monthly circRNA-Encoded GLP-1 Analogue, Demonstrates Durable Glycemic Control in T2D Rhesus Monkeys,” highlights the molecule’s ability to deliver (1) significant weight-loss effects, (2) strong glucose-lowering performance, and (3) long-term expression from a single dose. Pre-clinical data suggest that, leveraging the company’s circRNA-LNP platform, CR059 could support dosing intervals of one month and potentially extend to quarterly administration.

Management views ADA acceptance as external validation of PegBio’s R&D capabilities and expects the exposure to enhance the project’s international academic profile. CR059 remains in the research phase; timelines for clinical trials, regulatory approval, and commercialization are subject to uncertainty.

PegBio stated it will continue advancing CR059 and other pipeline assets and will provide further updates in line with Hong Kong listing regulations. The announcement was authorized by Chairman and Executive Director Dr. Michael Min Xu on 2 April 2026.